Drug Profile


Alternative Names: 16α-fluoro-DHEA; DHEA analogue 8354; HE 2500

Latest Information Update: 02 Feb 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Fels Institute for Cancer Research and Molecular Biology
  • Developer Aeson Therapeutics
  • Class Androstenols; Anorectics; Antihyperglycaemics; Antihyperlipidaemics; Antineoplastics; Small molecules; Testosterone congeners
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Asthma; Cancer; Cardiovascular disorders
  • Discontinued Actinic keratosis; Diabetes mellitus; Multiple sclerosis; Obesity; Psoriasis; Rheumatoid arthritis; Systemic lupus erythematosus

Most Recent Events

  • 02 Feb 2011 No development reported - Phase-I for Cancer in Switzerland (Parenteral)
  • 02 Feb 2011 No development reported - Phase-I for Cancer in United Kingdom (Parenteral)
  • 02 Feb 2011 No development reported - Phase-II for Cardiovascular disorders in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top